{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:06:36Z","timestamp":1775876796464,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ygyno.2022.10.021","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T15:27:47Z","timestamp":1669217267000},"page":"114-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy"],"prefix":"10.1016","volume":"168","author":[{"given":"David","family":"Mysona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Shaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bunja","family":"Rungruang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.10.021_bb0005","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/IJWH.S7012","article-title":"Clinical trials and progress with paclitaxel in ovarian cancer","volume":"2","author":"Kumar","year":"2010","journal-title":"Int. J. Women\u2019s Health"},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.021_bb0010","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/annonc\/mdh348","article-title":"Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy","volume":"15","author":"Cavaletti","year":"2004","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.021_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2014.12.021","article-title":"Neurotoxicity in ovarian cancer patients on gynecologic oncology group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG oncology\/gynecologic oncology group study","volume":"136","author":"Chase","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2022.10.021_bb0020","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1200\/JOP.2014.001776","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline summary","volume":"10","author":"Hershman","year":"2014","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ygyno.2022.10.021_bb0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2017.09.009","article-title":"The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"120","author":"Cliff","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.ygyno.2022.10.021_bb0030","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-011-1007-6","article-title":"Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer","volume":"67","author":"Bergmann","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.021_bb0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2015.11.011","article-title":"Chemotherapy-induced peripheral neuropathy: current status and progress","volume":"140","author":"Brewer","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.10.021_bb0040","series-title":"Medical Genetics Summaries","article-title":"Tamoxifen therapy and CYP2D6 genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.ygyno.2022.10.021_bb0045","series-title":"Medical Genetics Summaries","article-title":"Amitriptyline therapy and CYP2D6 and CYP2C19 genotype","author":"Dean","year":"2012"},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.021_bb0050","first-page":"6","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharm. J."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.021_bb0055","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14622416.3.2.229","article-title":"CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants","volume":"3","author":"Bradford","year":"2002","journal-title":"Pharmacogenomics."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.021_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/gim.2016.80","article-title":"Prediction of CYP2D6 phenotype from genotype across world populations","volume":"19","author":"Gaedigk","year":"2017","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.021_bb0065","article-title":"Results and challenges of cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population","volume":"7","author":"Salyakina","year":"2019","journal-title":"Mol. Genet. Genom. Med."},{"issue":"2","key":"10.1016\/j.ygyno.2022.10.021_bb0070","first-page":"121","article-title":"Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity","volume":"11","author":"Leskel\u00e4","year":"2011","journal-title":"Pharm. J."},{"issue":"9","key":"10.1016\/j.ygyno.2022.10.021_bb0075","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/phar.1970","article-title":"Prevalence of CYP3A5 genomic variances and their impact on tacrolimus dosing requirements among kidney transplant recipients in eastern North Carolina","volume":"37","author":"Maldonado","year":"2017","journal-title":"Pharmacotherapy."},{"issue":"4","key":"10.1016\/j.ygyno.2022.10.021_bb0080","first-page":"553","article-title":"CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis","volume":"20","author":"Khan","year":"2020","journal-title":"Pharm. J."},{"issue":"1","key":"10.1016\/j.ygyno.2022.10.021_bb0085","first-page":"61","article-title":"Genotype-guided tacrolimus dosing in African-American kidney transplant recipients","volume":"17","author":"Sanghavi","year":"2017","journal-title":"Pharm. J."},{"issue":"12","key":"10.1016\/j.ygyno.2022.10.021_bb0090","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-12-3786","article-title":"CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity","volume":"19","author":"de Graan","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2022.10.021_bb0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-019-03905-3","article-title":"Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes","volume":"84","author":"van Eijk","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"11","key":"10.1016\/j.ygyno.2022.10.021_bb0100","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/bjc.2016.326","article-title":"Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients","volume":"115","author":"Lam","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2022.10.021_bb0105","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","article-title":"CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel","volume":"24","author":"Hertz","year":"2013","journal-title":"Ann. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822018984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:03:51Z","timestamp":1758773031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822018984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":21,"alternative-id":["S0090825822018984"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}